Key result
Enzymatically modified LDL markedly boosts arachidonic acid mobilization and inflammatory TNF-alpha secretion versus native LDL.
Why the study?
The cellular responses and molecular mechanisms underlying the atherogenic effects of lipolytically modified LDL are incompletely understood.
Population
Human THP-1 monocytes prelabeled with [(3)H]arachidonic acid
Comparison
LDL modified by secretory PLA(2) or sphingomyelinase vs native LDL
Design
Preclinical experimental study
Authors
Loading...
Lipolytically modified LDL may alter monocyte AA metabolism; leaves open its role in atherosclerosis pending in vivo validation.
Lipolytically modified LDL by sPLA2 or SMase potentiates arachidonic acid release and cPLA2 activation in human monocytes, suggesting novel atherogenic properties.
Oestvang et al. (2004) studied Atherosclerosis. LDL lipolytically modified by secretory PLA2 (sPLA2) or bacterial sphingomyelinase (SMase) vs. Native LDL was evaluated on Extracellular release of arachidonic acid (AA) and cPLA2 activation. LDL modified by sPLA2 or SMase displayed a marked increase in arachidonic acid mobilization relative to native LDL, correlating with enhanced cPLA2 activity and TNF-alpha secretion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: